首页|期刊导航|中国临床药理学与治疗学|基于体内实验和网络药理学探究清肝二十七味丸对非酒精性脂肪性肝炎的作用及作用机制

基于体内实验和网络药理学探究清肝二十七味丸对非酒精性脂肪性肝炎的作用及作用机制OA

Mechanism of Qinggan Ershiqiwei Wan on non-alcoholic steatohep-atitis based on network pharmacology and in vivo experiments

中文摘要英文摘要

目的:基于体内实验和网络药理学探究清肝二十七味丸(QGW)对非酒精性脂肪性肝炎(NASH)的作用及作用机制.方法:利用高脂饲料(HFD)诱导 NASH 小鼠模型,分为正常组(CON)、模型组(HFD)、清肝二十七味丸给药组(HFD+QGW,HQG)每组 8只.第 7周开始,HQG 组给予药物连续作用至 14周,并监测各组小鼠体质量相关指数,14周结束,解剖小鼠观察肝脏外观和形态,利用 H&E 染色、Oil red O 染色方法观察小鼠肝组织的病理形态;比色法检测血清中的甘油三酯(TG)、总胆固醇(TC)、谷草转氨酶(AST)和谷丙转氨酶(ALT)含量;利用网络药理学通过数据库筛选 QGW 活性成分治疗NASH 的关键靶点,并对关键靶点进行基因及通路富集分析;通过酶联免疫吸附试验(ELISA)定量分析白细胞介素-1β(IL-1β)、IL-6水平,West-ern blot 及免疫组织化学实验对 MAPK 信号通路进行验证.结果:动物实验结果表明,经 QGW 干预模型小鼠 8 周后,可显著降低小鼠血清 TG、TC、ALT、AST 水平(P<0.01);H&E 染色、油红 O 染色观察到 QGW 显著改善 HFD 诱导肝脏组织中细胞排列紊乱、脂质蓄积和炎症浸润;网络药理学结果表明,共筛选得到 18个核心成分,包括 stylopine、7beta-senecioyloxyoplopa-3(14)Z,8(10)-di-en-2-one、(1R,3R,4R,5S,6S)-1-acetoxy-8-an-geloxoyloxy-3,4-epoxy-5-hydroxybisabola-7(14),10-dien-2-one、7beta-(3-ethyl-cis-crotonoyloxy)-14-hydroxy-notonipetranone、木犀草素等;25个核心靶点包括 MAKP8、MAPK14、MAPK9、IL-6等,涉及包括 MAPK 信号通路在内的 20条通路;ELISA实验表明,QGW 显著降低小鼠血清中 IL-1β、IL-6水平(P<0.01),Western blot 及免疫组织化学实验结果表明,与 CON 组相比,HFD 组 p-ERK/ERK、p-JNK/JNK、p-P38/P38蛋白水平显著升高(P<0.01),与 HFD 组相比,HQG 组 p-ERK/ERK、p-JNK/JNK、p-P38/P38蛋白水平显著降低(P<0.05,P<0.01).结论:QGW 改善 HFD 诱导的 NASH 小鼠肝脏脂质蓄积及炎症浸润,其作用机制可能与抑制 MAPK 信号通路相关.

AIM:Through in vivo experiments and network pharmacology,the effects and mecha-nisms of Qinggan Ershiqiwei Wan(QGW)on non-al-coholic steatohepatitis(NASH)was explored.METHODS:A NASH mouse model was established by feeding a high-fat diet(HFD)induction.The C57BL/6J mice were divided into three groups:the normal group(CON),the model group(HFD),and the QGW administration group(HFD+QGW,HQG),with 8 mice in each group.Starting from the 7th week,the HQG group was administered the drug continuously until the 14th week,and the body weight-related indices of each group of mice were monitored.At the end of the 14th week,the mice were dissected to observe the appearance and mor-phology of the liver.Pathological morphology of the liver tissue was observed using H&E staining and Oil red O staining methods.The serum levels of triglyc-erides(TG),total cholesterol(TC),aspartate amino-transferase(AST)and alanine aminotransferase(ALT)were detected by colorimetry.Network phar-macology was used to screen key targets of QGW active components for the treatment of NASH through databases,and gene and pathway enrich-ment analysis was performed on the key targets.The levels of interleukin-1β(IL-1β)and IL-6 were quantitatively analyzed by enzyme-linked im-munosorbent assay(ELISA),and the MAPK signal-ing pathway was experimentally validated by West-ern blot and immunohistochemistry.RESULTS:Ani-mal experiments demonstrated that after 8 weeks of QGW intervention in model mice,serum levels of TG,TC,ALT and AST were significantly reduced(P<0.01).H&E staining and Oil Red O staining re-vealed that QGW significantly ameliorated the dis-ordered cell arrangement,lipid accumulation,and inflammatory infiltration in liver tissues induced by HFD.Network pharmacology results revealed the screening of 18 core components,including stylop-ine,7β-senecioyloxyoplopa-3(14)Z,8(10)-dien-2-one,(1R,3R,4R,5S,6S)-1-acetoxy-8-angeloxoyloxy-3,4-epoxy-5-hydroxybisabola-7(14),10-dien-2-one,7β-(3-ethyl-cis-crotonoyloxy)-14-hydroxy-no-tonipetranone,and luteolin;the 25 core targets,in-cluding MAKP8,MAPK14,MAPK9,and IL-6,were screened,involving 20 pathways including the MAPK signaling pathway.ELISA experiments demonstrated that QGW reduced the levels of IL-1β and IL-6 in the serum of mice(P<0.01).Western blot and immunohistochemistry results indicated that,compared to the CON group,the protein lev-els of p-ERK/ERK,p-JNK/JNK,and p-P38/P38 were significantly increased in the HFD group(P<0.01).In comparison to the HFD group,the protein levels of p-ERK/ERK,p-JNK/JNK,and p-P38/P38 were de-creased in the HQG group(P<0.05,P<0.01).CON-CLUSION:QGW alleviates hepatic lipid accumula-tion and inflammatory infiltration in HFD-induced NASH mice,with its mechanism likely related to the inhibition of the MAPK signaling pathway.

高晓艳;郭娟;黄圣;王巧云;黄俣佳;李金媛;刘晓强

赤峰大学基础医学院 内蒙古人类遗传病研究自治区高等学校重点实验室,赤峰 024000,内蒙古赤峰大学基础医学院 内蒙古人类遗传病研究自治区高等学校重点实验室,赤峰 024000,内蒙古赤峰大学基础医学院 内蒙古人类遗传病研究自治区高等学校重点实验室,赤峰 024000,内蒙古赤峰大学基础医学院 内蒙古人类遗传病研究自治区高等学校重点实验室,赤峰 024000,内蒙古赤峰大学基础医学院 内蒙古人类遗传病研究自治区高等学校重点实验室,赤峰 024000,内蒙古赤峰大学基础医学院 内蒙古人类遗传病研究自治区高等学校重点实验室,赤峰 024000,内蒙古赤峰市医院,赤峰 024000,内蒙古

医药卫生

清肝二十七味丸非酒精性脂肪肝炎网络药理学MAPK 信号通路

Qinggan Ershiqiwei WanNASHnet-work pharmacologyMAPK signaling pathway

《中国临床药理学与治疗学》 2026 (5)

596-606,11

内蒙古自治区自然科学基金资助项目(2024QN08069)赤峰学院2026年度博士科研创新发展基金项目(BSJJ015)赤峰市科协自然科学科研课题(SZR2025010)赤峰学院大学生创新创业训练计划项目(S202410138041,202510138051)赤峰学院2024年第二批百名博士下基层服务地方项目(2024FWDF32)

10.12092/j.issn.1009-2501.2026.05.003

评论